Wow, my blog on abiraterone in advanced prostate cancer got picked up last night by TopUSAsites for prostate cancer. It looks like the drug is going to be a hot topic for a while, but caution against the hype is advised until we see whether reduction in PSA and tumour shrinkage actually translates to what [...]
Entries Tagged as 'company news'
15 minutes of fame in oncology
July 23rd, 2008 · No Comments · Cougar, cancer, company news, competitive intelligence, market intelligence, market trends, oncology, prostate
Tags:
Cervical cancer vaccines
June 22nd, 2008 · No Comments · cancer, cervical cancer, company news, competitive intelligence, market intelligence, market trends, skin cancer
The UK has recently approved a second vaccine that protects against HPV called Cervarix from GSK, in addition to Gardasil from Merck. Both vaccines protect against HPV, but Gardasil also protects against gentical warts, which Cervarix does not. Male with genital warts – image courtesy of Wikipedia The wholesale price for the two is exactly [...]
Tags:
Erbitux extends overall survival by 5 weeks in lung cancer
June 2nd, 2008 · No Comments · cancer, company news, competitive intelligence, lung cancer, market intelligence, market trends, oncology
ImClone announced that late-stage study data showed that first-line treatment with Erbitux (cetuximab) plus standard chemotherapy significantly increased overall survival by about five weeks in patients with advanced non-small cell lung cancer (NSCLC), compared with chemotherapy alone. The results were presented at the American Society of Clinical Oncology (ASCO) meeting this weekend. To put things [...]
Tags:
Market trends: cancer vs. ophthalmology drugs
May 14th, 2008 · No Comments · company news, competitive intelligence, market intelligence, market trends, oncology, ophthalmology
Today I was at the ophthalmologists office getting my eyes tested for some new glasses. The technician and I were chatting convivially about the pros and cons of Avastin versus Lucentis for wet age-related macular degeneration (AMD). Later, while looking at the National Institutes of Health (NIH) site on the internet, I noticed they have [...]
Tags:
AZ and Iressa attempting a comeback in lung cancer?
May 9th, 2008 · No Comments · cancer, company news, competitive intelligence, lung, market intelligence, market trends, oncology
Last week, AstraZeneca announced the submission of a marketing authorisation application to the European Medicines Agency (EMEA) for its oral anti-cancer drug, gefitinib (IRESSA™) as a treatment for locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have been pre-treated with platinum-containing chemotherapy. The application was based on data from the Phase [...]
Tags:
Market intelligence – when NICE is not so nice
April 29th, 2008 · No Comments · Roche, Tarceva, company news, competitive intelligence, market intelligence, market trends
The National Institute for Health and Clinical Excellence (NICE) have announced their decision not to recommend the use of Tarceva (erlotinib) for the treatment of locally-advanced or metastatic non-small-cell lung cancer (NSCLC) in the National Health Service (NHS) in England and Wales. NICE’s Final Appraisal Determination (FAD) on Tarceva last week concluded that the drug [...]
Tags: